Increased expression of the WNT antagonist sFRP-1 in glaucoma elevates intraocular pressure

Journal of Clinical Investigation

Volumn 118, Issue 3, 2008, Pages 1056-1064

  Wang, Wan Heng ^a   McNatt, Loretta G ^a   Pang, Iok Hou ^a   Millar, J Cameron ^a   Hellberg, Peggy E ^a   Hellberg, Mark H ^a   Steely, H Thomas ^a   Rubin, Jeffrey S ^b   Fingert, John H ^c   Sheffield, Val C ^c,d   Stone, Edwin M ^c,d   Clark, Abbot F ^a  

^a ALCON RESEARCH LTD   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA CATENIN; SECRETED FRIZZLED RELATED PROTEIN 1; WNT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GLAUCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAOCULAR PRESSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK;

AMINO ACID SEQUENCE; ANIMALS; BETA CATENIN; CELLS, CULTURED; GLAUCOMA; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRAOCULAR PRESSURE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK; WNT PROTEINS;

EID: 40549098396     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33871     Document Type: Article

References (58)

1. Quigley, H.A. 1996. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 80:389-393.
2. Quigley, H.A. 1998. The search for glaucoma genes - implications for pathogenesis and disease detection. N. Engl. J. Med. 338:1063- 1064.
3. Quigley, H.A. 1993. Open-angle glaucoma. N. Engl. J. Med. 328:1097-1106.
4. Kass, M.A., et al. 2002. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:701-713; discussion 829-830.
5. The AGIS Investigators. 2000. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am. J. Ophthalmol. 130:429-440.
6. Heijl, A., et al. 2002. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120:1268-1279.
7. Leske, M.C., Connell, A.M., Wu, S.Y., Hyman, L.G., and Schachat, A.P. 1995. Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch. Ophthalmol. 113:918-924.
8. Sommer, A., et al. 1991. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch. Ophthalmol. 109:1090-1095.
9. Gordon, M.O., et al. 2002. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:714-720; discussion 829-830.
10. Nishimura, D.Y., et al. 1998. The forkhead transcription factor gene FKHL7 is responsible for glaucoma phenotypes which map to 6p25. Nat. Genet. 19:140-147.
11. Fingert, J.H., et al. 1999. Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. Hum. Mol. Genet. 8:899-905.
12. Libby, R.T., Gould, D.B., Anderson, M.G., and John, S.W. 2005. Complex genetics of glaucoma susceptibility. Annu. Rev. Genomics Hum. Genet. 6:15-44.
13. Liton, P.B., Luna, C., Challa, P., Epstein, D.L., and Gonzalez, P. 2006. Genome-wide expression profile of human trabecular meshwork cultured cells, nonglaucomatous and primary open angle glaucoma tissue. Mol. Vis. 12:774-790.
14. Wang, N., Chintala, S.K., Fini, M.E., and Schuman, J.S. 2001. Activation of a tissue-specific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype. Nat. Med. 7:304-309.
15. Bhattacharya, S.K., Peachey, N.S., and Crabb, J.W. 2005. Cochlin and glaucoma: a mini-review. Vis. Neurosci. 22:605-613.
16. Bhattacharya, S.K., et al. 2005. Proteomics reveal Cochlin deposits associated with glaucomatous trabecular meshwork. J. Biol. Chem. 280:6080-6084.
17. Shepard, A.R., et al. 2007. Glaucoma-causing myocilin mutants require the Peroxisomal targeting signal-1 receptor (PTS1R) to elevate intraocular pressure. Hum. Mol. Genet. 16:609-617.
18. Finch, P.W., et al. 1997. Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc. Natl. Acad. Sci. U. S. A. 94:6770-6775.
19. Uren, A., et al. 2000. Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling. J. Biol. Chem. 275:4374-4382.
20. Witherington, J., et al. 2003. 5-aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 13:1581-1584.
21. Fautsch, M.P., Bahler, C.K., Jewison, D.J., and Johnson, D.H. 2000. Recombinant TIGR/MYOC increases outflow resistance in the human anterior segment. Invest. Ophthalmol. Vis. Sci. 41:4163-4168.
22. Ezan, J., et al. 2004. FrzA/sFRP-1, a secreted antagonist of the Wnt-Frizzled pathway, controls vascular cell proliferation in vitro and in vivo. Cardiovasc. Res. 63:731-738.
23. Partanen, J. 2007. FGF signalling pathways in development of the midbrain and anterior hindbrain. J. Neurochem. 101:1185-1193.
24. Seifert, J.R., and Mlodzik, M. 2007. Frizzled/PCP signalling: a conserved mechanism regulating cell polarity and directed motility. Nat. Rev. Genet. 8:126-138.
25. Clevers, H. 2006. Wnt/beta-catenin signaling in development and disease. Cell. 127:469-480.
26. Turashvili, G., Bouchal, J., Burkadze, G., and Kolar, Z. 2006. Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology. 73:213-223.
27. Lee, H.X., Ambrosio, A.L., Reversade, B., and De Robertis, E.M. 2006. Embryonic dorsal-ventral signaling: secreted frizzled-related proteins as inhibitors of tolloid proteinases. Cell. 124:147-159.
28. Ille, F., et al. 2006. Wnt/BMP signal integration regulates the balance between proliferation and differentiation of neuroepithelial cells in the dorsal spinal cord. Dev. Biol. 304:394-408.
29. Apte, U., et al. 2007. beta-Catenin is critical for early postnatal liver growth. Am. J. Physiol. Gastrointest. Liver Physiol. 292:G1578-G1585.
30. Kuure, S., Popsueva, A., Jakobson, M., Sainio, K., and Sariola, H. 2007. Glycogen synthase kinase-3 inactivation and stabilization of beta-catenin induce nephron differentiation in isolated mouse and rat kidney mesenchymes. J. Am. Soc. Nephrol. 18:1130-1139.
31. Prall, F., Weirich, V., and Ostwald, C. 2007. Phenotypes of invasion in sporadic colorectal carcinomas related to aberrations of the adenomatous polyposis coli (APC ) gene. Histopathology. 50:318-330.
32. Coffin, C.M., Hornick, J.L., Zhou, H., and Fletcher, C.D. 2007. Gardner fibroma: a clinicopathologic and immunohistochemical analysis of 45 patients with 57 fibromas. Am. J. Surg. Pathol. 31:410-416.
33. Nojima, M., et al. 2007. Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene. 26:4699-4713.
34. Rubin, J.S., Barshishat-Kupper, M., Feroze-Merzoug, F., and Xi, Z.F. 2006. Secreted WNT antagonists as tumor suppressors: pro and con. Front. Biosci. 11:2093-2105.
35. de Iongh, R.U., Abud, H.E., and Hime, G.R. 2006. WNT/Frizzled signaling in eye development and disease. Front. Biosci. 11:2442-2464.
36. Kumar, S., Leontovich, A., Coenen, M.J., and Bahn, R.S. 2005. Gene expression profiling of orbital adipose tissue from patients with Graves' ophthalmopathy: a potential role for secreted frizzledrelated protein-1 in orbital adipogenesis. J. Clin. Endocrinol. Metab. 90:4730-4735.
37. Tripathi, R.C., Li, J., Chan, W.F., and Tripathi, B.J. 1994. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp. Eye Res. 59:723-727.
38. Inatani, M., et al. 2001. Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes. Graefes Arch. Clin. Exp. Ophthalmol. 239:109-113.
39. Picht, G., Welge-Luessen, U., Grehn, F., and Lutjen-Drecoll, E. 2001. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch. Clin. Exp. Ophthalmol. 239:199-207.
40. Yamamoto, N., Itonaga, K., Marunouchi, T., and Majima, K. 2005. Concentration of transforming growth factor beta2 in aqueous humor. Ophthalmic Res. 37:29-33.
41. Gadue, P., Huber, T.L., Paddison, P.J., and Keller, G.M. 2006. Wnt and TGF-beta signaling are required for the induction of an in vitro model of primitive streak formation using embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 103:16806-16811.
42. Labbé, E., et al. 2007. Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer Res. 67:75-84.
43. Edlund, S., et al. 2005. Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis. Mol. Cell. Biol. 25:1475-1488.
44. Sato, M. 2006. Upregulation of the Wnt/beta-catenin pathway induced by transforming growth factor-beta in hypertrophic scars and keloids. Acta Derm. Venereol. 86:300-307.
45. Jian, H., et al. 2006. Smad3-dependent nuclear translocation of beta-catenin is required for TGF-beta1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. Genes Dev. 20:666-674.
46. Wordinger, R.J., et al. 2007. Effects of TGF-beta2, BMP-4, and gremlin in the trabecular meshwork: implications for glaucoma. Invest. Ophthalmol. Vis. Sci. 48:1191-1200.
47. Zechner, D., et al. 2007. Bmp and Wnt/beta-catenin signals control expression of the transcription factor Olig3 and the specification of spinal cord neurons. Dev. Biol. 303:181-190.
48. Raible, D.W. 2006. Development of the neural crest: achieving specificity in regulatory pathways. Curr. Opin. Cell Biol. 18:698-703.
49. Chen, Y., et al. 2007. Beta-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation. J. Biol. Chem. 282:526-533.
50. Liu, Z., Tang, Y., Qiu, T., Cao, X., and Clemens, T.L. 2006. A dishevelled-1/Smad1 interaction couples WNT and bone morphogenetic protein signaling pathways in uncommitted bone marrow stromal cells. J. Biol. Chem. 281:17156-17163.
51. Wang, W.H., et al. 2001. Optimal procedure for extracting RNA from human ocular tissues and expression profiling of the congenital glaucoma gene FOXC1 using quantitative RT-PCR. Mol. Vis. 7:89-94.
52. Steely, H.T., et al. 1992. The effects of dexamethasone on fibronectin expression in cultured human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 33:2242-2250.
53. Clark, A.F., et al. 1994. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 35:281-294.
54. Shepard, A.R., et al. 2001. Delayed secondary glucocorticoid responsiveness of MYOC in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 42:3173-3181.
55. Pang, I.H., McCartney, M.D., Steely, H.T., and Clark, A.F. 2000. Human ocular perfusion organ culture: a versatile ex vivo model for glaucoma research. J. Glaucoma. 9:468-479.
56. Clark, A.F., Wilson, K., de Kater, A.W., Allingham, R.R., and McCartney, M.D. 1995. Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. Invest. Ophthalmol. Vis. Sci. 36:478-489.
57. Tschumper, R.C., Johnson, D.H., Bradley, J.M., and Acott, T.S. 1990. Glycosaminoglycans of human trabecular meshwork in perfusion organ culture. Curr. Eye Res. 9:363-369.
58. Wang, W.H., Millar, J.C., Pang, I.H., Wax, M.B., and Clark, A.F. 2005. Noninvasive measurement of rodent intraocular pressure with a rebound tonometer. Invest. Ophthalmol. Vis. Sci. 46:4617-4621.